NAGE Announces Higher Full-Year 2025 Outlook; Exhibit 99.1 Furnished

Rhea-AI Filing Summary

Niagen Bioscience, Inc. disclosed in a Current Report on Form 8-K that on October 6, 2025 it issued a press release announcing an increase to its financial outlook for the full year ending December 31, 2025. The company states the press release is furnished as Exhibit 99.1 and clarifies this information is being furnished, not filed, under the Exchange Act so it is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated. No specific revenue, earnings, or guidance figures are included in the filing text provided.

Positive

• Company increased full-year 2025 financial outlook, indicating management expects stronger results
• Press release furnished as Exhibit 99.1, providing a timely disclosure channel to investors

Negative

• Filing text does not include specific guidance figures, requiring review of Exhibit 99.1 for material detail
• Information furnished, not filed, which limits Section 18 liability and may affect incorporation into other filings

Insights

Corporate Finance Analyst

Raised outlook is generally positive but lacks disclosed figures.

The company formally notified investors that it has increased its full-year 2025 financial outlook and furnished a press release as Exhibit 99.1. An upward revision to outlook typically signals management expects stronger operating or financial results for the year ending December 31, 2025.

Because the filing text does not include the new numeric guidance, investors must review Exhibit 99.1 to assess magnitude and drivers. Watch the furnished press release for specific revenue or EPS figures and any explanation of operational drivers over the next few days.

Compliance & Investor Relations Specialist

Furnishing the release limits legal exposure but reduces formal filing impact.

The company explicitly states the announcement is being furnished, not filed, which limits Section 18 liability and means the content is not automatically incorporated into future SEC filings. This is a standard disclosure practice for timely communications.

Investors seeking authoritative detail should consult the furnished Exhibit 99.1; absence of figures in the 8-K summary creates short-term information asymmetry until the exhibit is reviewed, likely within days.

0001386570FALSE00013865702025-10-062025-10-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2025

NIAGEN BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-37752

26-2940963

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024

(Address of principal executive offices, including zip code)

(310) 388-6706

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			NAGE			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.     Regulation FD Disclosure.

On October 6, 2025, Niagen Bioscience, Inc. (the “Company”) issued a press release announcing that it has increased its financial outlook for the full year ending December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number						Description
99.1						Press Release dated October 6, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NIAGEN BIOSCIENCE, INC.
Dated: October 6, 2025			By:			/s/ Ozan Pamir
						Name: Ozan Pamir
						Chief Financial Officer
						(principal financial officer and duly authorized on behalf of the registrant)

FAQ

What did Niagen Bioscience (NAGE) announce on October 6, 2025?

The company announced it has increased its financial outlook for the full year ending December 31, 2025 and furnished a press release as Exhibit 99.1.

Does the 8-K include the updated numerical guidance for 2025?

No. The filing text states the outlook was increased but does not include specific revenue or earnings figures; those should appear in Exhibit 99.1.

Is the October 6, 2025 announcement considered "filed" with the SEC?

No. The company states the information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference unless explicitly stated.

Where can investors find the detailed updated outlook?

Investors should review Exhibit 99.1, the furnished press release referenced in the Form 8-K, for the detailed guidance and any supporting figures.

Does the 8-K disclose reasons for the increased outlook?

No. The provided filing text does not state the reasons or drivers; such explanations may be included in the furnished press release.